Research Paper Volume 15, Issue 15 pp 7476—7495
SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC
Figure 4. SETBP1 mutations determined the sensitivity to ICI treatments in NSCLC. (A) ICI survival differences between SETBP1 mutated and wild-type subgroups. (B) A multivariate Cox regression analysis was performed to verify the connection between SETBP1 mutations and ICI prognosis. (C) ICI response rate differences of SETBP1 two subgroups. (D) A multivariate logistic regression analysis was performed to verify the connection between SETBP1 mutations and ICI response rate.